Among the bumper crop of approval recommendations from the EU’s Committee for Medicinal Products for Human Use (CHMP) announced Sept. 26 were Gilead Sciences Inc.’s hepatitis C combination Harvoni (sofosbuvir plus ledipasvir), AstraZeneca PLC’s opioid-induced constipation therapy Moventig (naloxegol), and Almirall SA’s twice-daily COPD therapy Duaklir Genuir (aclidinium plus formoterol fumarate dehydrate).
In total, 15 new products, containing seven new molecular entities, were recommended for marketing approval in Europe following the CHMP’s meeting on Sept. 22 through to Sept. 25, including filings from Eli Lilly & Co
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?